SINTX AND EU CONSORTIUM COLLABORATE IN SILICON NITRIDE DEVELOPMENT
April 03 2019 - 9:00AM
SINTX Technologies, an innovative biomaterials and OEM company that
develops and manufactures biomedical silicon nitride, announced a
key partnership with a multi-center European industry-academic
group that aims to train future scientists, and promote the
development of silicon nitride biomedical implants. As partner and
senior advisor to the program, SINTX will participate in technical
reviews of the program, and will host graduate students during the
course of the program.
Program Synopsis
Silicon nitride offers the mechanical strength,
chemical stability, and biocompatibility needed to manufacture
spinal implants. To promote research, and to train future
scientists, the European Union’s Horizon 2020 research and
Innovation Program funded a four year (2019-2022) grant targeted
specifically at developing spinal implants. Led by Professor
Cecilia Persson at Uppsala University, the consortium has three
university participants (Uppsala University, ETH Zürich, and
University of Leeds); several industrial partners (IHI Ionbond AG,
CeramTec GmbH, Key Engineering Solutions, SINTX Technologies, and
OssDsign AB) and the Leeds Teaching Hospitals NHS Trust as clinical
collaborators. In addition to the focus on spinal implants, the
program aims to deliver 15 PhD scientists through a comprehensive,
multi-center research and training effort.
Persson, who is also a Board Member of the
Scandinavian Society of Biomaterials, stated “The inclusion of
SINTX Technologies in this project is considered to be of very high
value to the consortium, in view of their many years of experience
in silicon nitride-based materials for use in biomedical
applications. We have also worked with these materials for some
time and find them particularly promising in certain spinal
applications.”
“This consortium is another validation of our
deep bench of published research in silicon nitride. It is
gratifying to see others recognize the value of silicon nitride as
a biomaterial,” said Dr. Sonny Bal, President and CEO at SINTX
Technologies. “We are honored to be an industrial partner of the
European consortium, an academic and industrial collaboration that
will boost our R&D, cross-fertilize our intellectual resources,
expand the field, and help train future professionals.” “In
addition to the consortium, recent papers from the Texas A&M
School of Dentistry, and the University of Rochester have
corroborated our earlier data regarding silicon nitride. In 2018,
Australian investigators reported successful outcomes with an
earlier composition of silicon nitride; their data is the longest
known follow-up of any spine biomaterial. In 2019, another
scientific report from China confirmed our previously-reported
osteogenic and antibacterial properties of silicon nitride. These
independent sources validate and add credibility to our work; we
welcome the added, outside interest in silicon nitride that will
create new commercial opportunities for SINTX in spine and beyond,”
added Dr. Bal.
This project has received funding from the
European Union’s Horizon 2020 research and innovation program under
grant agreement No. 812765.
About SINTX Technologies
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for biomedical
applications, such as spine and dental implants. The core strength
of SINTX Technologies is the research and development of
medical-grade silicon nitride ceramics for external partners. The
Company presently manufactures silicon nitride spinal implants in
its ISO 13485 certified manufacturing facility for CTL-Amedica, the
exclusive retail channel for silicon nitride spinal implants.
For more information on SINTX Technologies or
its silicon nitride material platform, please
visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (“PSLRA”) that are subject to a number of risks
and uncertainties. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management’s current
estimates, projections, expectations and beliefs. A discussion of
those risks and uncertainties can be found in SINTX's Risk Factors
disclosure in its Annual Report on Form 10-K, filed with the
Securities and Exchange Commission (SEC) on March 11, 2019, and in
SINTX's other filings with the SEC. SINTX disclaims any obligation
to update any forward-looking statements. SINTX undertakes no
obligation to publicly revise or update the forward-looking
statements to reflect events or circumstances that arise after the
date of this report. Contacts:
SINTX Technologies 801-839-3502 IR@sintx.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Aug 2024 to Sep 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Sep 2023 to Sep 2024